Du er her: IRF Lægemiddelspørgsmål Referencer til "SSRI og graviditet – risiko for misdannelser?"

Print

Referencer til "SSRI og graviditet – risiko for misdannelser?

  • Alwan S, Reefhuis J, Rasmussen S et al. Maternal use of selective serotonin reuptake inhibitors and risk for birth defects. [Abstract]. Teratology society abstracts 2005; 292.
  • Chambers CD, Johnson KA, Dick LM et al. Birth outcomes in pregnant women taking fluoxetine. N Eng J Med.; 1996; 335(14): 1010-15.
  • Chambers CD, Hernadez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persiostent pulmonary hypertension of the newborn. N Eng J Med; 2006; 354(6):579-587.
  • Chambers C, Hernandez-Diaz S and Mitchell AA. N Engl J Med 354; 20: 2188-2189 (The Authors reply).
  • Cohen et al. Relapse of Major Depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507.
  • Diav-Citrin O, Schechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reprod Toxicol; 2005; 20: 459 [abstract].
  • DSAM vejledning. Diagnostik og behandling af depression i almen praksis, 2001.
  • Eberhard-Gran M, Eskild A, Opjordsmoen S. Treating Mood Disorders during pregnancy. Drug Safety; 2005; 28(8): 695-706.
  • Einarson TR, A Einerson. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidem Drug Science; 2005.
  • Ericson A, Källen B-E. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Epidemiol 1999; 55: 503-8.
  • Glasmann AH and Stage KB. Depressed Patients with cardiovascular disease – treatment considerations. CNS Drugs 1981; 1(6):435-440.
  • GlaxoSmithKline Clinical Trial Register. Epidemiology Study: Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation (http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp).
  • Hallberg P, Odlind V. and Sjöblom V. N Engl J Med 354; 20: 2188-2189 (Letter to the Editor).
  • Koren G, Nulman I, Addis A. Outcome of children exposed in utero to fluoxetine: a critical review. Depression and Anxiety 1998; 8(1): 27-31.
  • Källén B, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol; 2003; 17: 255-61.
  • Källén B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol; 2006;21(3):221-222.
  • Loughhead AM, Stowe ZN, Newport DJ, et al. Placental passage of tricyclic antidepressants. Biol Psych: 2006;59: 287-290.
  • Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A., Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365:482-87.
  • SBU rapporten: Behandling af depressionssjukdomer – en systematisk litteraturoversigt, vol 3. www.sbu.se.
  • Spigset O, Hägg S. Nya antidepressiva läkemedel under graviditet och amning. Läkartidningen 2004;101(13):1176-1181.
  • Stage KB. Younger and Elderly Depressed Inpatients. I) Differences in Symptomatology and diagnostic profile, II) Adverse drug reactions to clomipramine. Ph.D. thesis. Dept. of Psych, Odense University Hospital, Denmark. 1996.
  • www.laegemiddelstyrelsen.dk - Lægemiddelstyrelsens netsted. "Seroxat og risiko for fosterskader" (9. nov. 2005)
  • Wogelius, P et al. Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcomes. Pharmacoepidemiol drug safety 2005; 14: S72:3 [abstract]. http://www.laegemiddelstyrelsen.dk/db/filarkiv/5611/Pharmacoepidemiology_2005.pdf.
Institut for Rationel Farmakoterapi, 29. juni 2006


 

Siden sidst opdateret: 22. december 2006 Print Printspacer Tip en ven Tip en ven/kollega spacerTil top Til top